The SELECT-EARLY MTX-controlled trial examined the safety and efficacy of upadacitinib, a potent, reversible jakinib, as monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to methotrexate.
![](https://www.the-rheumatologist.org/wp-content/uploads/2015/10/THR_1015_pg92a-150x150.jpg)